Results 251 to 260 of about 208,828 (307)

Phase I study of domatinostat (4SC‐202), a class I histone deacetylase inhibitor in patients with advanced hematological malignancies

European Journal of Haematology, 2019
Domatinostat (4SC‐202) is a selective class I histone deacetylase inhibitor (HDACi). This phase I study investigated safety, tolerability, pharmacokinetics (PK), pharmacodynamics, and antitumor activity in patients with advanced hematological ...
B. von Tresckow, C. Sayehli, W. Aulitzky, M. Goebeler, M. Schwab, Eunice Braz, Babett Krauss, R. Krauss, F. Hermann, R. Bartz, A. Engert   +10 more
semanticscholar   +1 more source

Carbamazepine is an inhibitor of histone deacetylases

Life Sciences, 2005
Carbamazepine (CBZ) is a common antiepileptic drug (AED) that acts through multiple mechanisms including blockade and potentiation of cation channels and modulation of neurotransmitter levels. Whether it affects any component of the gene transcription machinery is unknown.
Andreas S, Beutler, SiDe, Li, Rebekka, Nicol, Martin J, Walsh   +3 more
openaire   +2 more sources

Selective Histone Deacetylase Inhibitors

Anti-Cancer Agents in Medicinal Chemistry, 2012
Histone deacetylases (HDACs) are a family of conserved metalloproteases which play a key role in the development of cancer. They can be divided into 18 subtypes according to their structural diversity. Histone deacetylase inhibitors are considered as potential anti-cancer agents and a lot of pan-HDAC inhibitors have entered clinical trials.
Huili, Pan, Jiangying, Cao, Wenfang, Xu
openaire   +2 more sources

Histone deacetylase inhibitors

European Journal of Medicinal Chemistry, 2005
AbstractFor Abstract see ChemInform Abstract in Full Text.
openaire   +4 more sources

Histone Deacetylase Inhibitors

2004
The base sequence of DNA provides the genetic code for proteins. The regulation of expression or suppression of gene transcription is largely determined by the structure of the chromatin--referred to as epigenetic gene regulation (Agalioti et al., 2002; Jenuwein and Allis, 2001; Richards and Elgin, 2002; Spotswood and Turner, 2002; Zhang and Reinberg ...
Paul A, Marks, Victoria M, Richon, Thomas, Miller, William Kevin, Kelly   +3 more
openaire   +2 more sources

Prospects: Histone deacetylase inhibitors

Journal of Cellular Biochemistry, 2005
AbstractHistone deacetylase (HDAC), inhibitors represent a new class of targeted anti‐cancer agents. Several of these compounds are in clinical trials with significant activity against a spectrum of both hematologic and solid tumors at doses that are well tolerated by the patients.
Milos, Dokmanovic, Paul A, Marks
openaire   +2 more sources

Histone deacetylase inhibitors in lymphoma

Current Opinion in Oncology, 2010
Although many advances have been made in the treatment of lymphoma in the past decade, the treatment of patients with relapsed and refractory disease remains challenging. Only a fraction of patients will be cured with salvage therapy and transplantation.
Amanda, Copeland, Daniela, Buglio, Anas, Younes   +2 more
openaire   +2 more sources

Histone Deacetylase Inhibitors In Inflammatory Disease

Current Topics in Medicinal Chemistry, 2009
Lysine acetylation is becoming increasingly appreciated as a key post-translational modification in the endogenous regulation of protein function. The so-called histone acetyl transferases (HATs) and histone deacetylases (HDACs), best known for their roles in controlling chromatin remodeling via histone acetylation/deacetylation, are now known to ...
Halili, M. A., Andrews, M, Sweet, M., Fairlie, D. P.   +3 more
openaire   +5 more sources

Function of Histone Deacetylase Inhibitors in Inflammation

Critical Reviews™ in Immunology, 2011
Histone deacetylases (HDACs) display multi-faceted roles in coordinating the interaction of intracellular signaling pathways with chromatin remodeling and transcription factor function to finely specify gene alterations and maintenance of gene expression during cellular activation, proliferation, and differentiation. These processes, epigenetic and non-
Grabiec, Aleksander M., Tak, Paul P., Reedquist, Kris A.   +2 more
openaire   +4 more sources

Histone Deacetylase Inhibitors

2021
Histone Deacetylase Inhibitors (HDACi) inhibits deacetylases of histones and nonhistones. As such it has potential widespread biological effects. However, cancer cells are preferentially affected than normal cells making it a useful targeted therapy in cancer.
Opelo Sefhore, Silvia CW Ling
openaire   +1 more source